ClinicalTrials.gg
CompletedNCT07771998ADOPSUpdated Nov 2, 2026

Dermal and Ophthalmological Acceptability Assessment in Sensitive Skin

An interventional study of Blancy Pro in Sensitive Skin, sponsored by Brainfarma Industria Química e Farmacêutica S/A. Completed at 1 site in Brazil. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Not applicable, Interventional, and Other

Updated Nov 2, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.

02

Conditions studied

  • Sensitive Skin
03

In context

Lead sponsor

Brainfarma Industria Química e Farmacêutica S/A is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 to 60 years.
  • Participants with any skin type, with at least 25% representation of each skin type.
  • Participants with sensitive skin, clinically confirmed by the Stinging Test.
  • Intact skin in the assessment area.
  • Willingness to comply with all study procedures and attend scheduled visits and assessments.
  • Ability to understand, provide written , and sign the Informed Consent Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.
  • Use of anti-inflammatory, , or antihistamine medications within 3 weeks prior to screening.
  • Skin marks or conditions in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.
  • History of atopic disease or allergy to cosmetic products.
  • Active skin diseases and/or lesions in the assessment area or elsewhere on the body.
  • Immunosuppression due to medication use or active disease.
  • Uncontrolled endocrine disorders.
  • Relevant medical history or current evidence of alcohol or drug abuse.
  • Known history or suspected intolerance to products of the same category as the product.
  • Intense sun exposure within 15 days prior to assessment.
  • Aesthetic or dermatological treatments within 4 weeks prior to assessment.
  • Any other condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.
  • Participants with entropion, ectropion, hordeolum (stye), conjunctivitis, uveitis, or other active ocular diseases at screening.
  • Participants with corneal ulceration, blepharitis, meibomitis, pterygium, trichiasis, distichiasis, or other moderate to severe ocular disorders.
  • Initiation of contact lens use within 1 week prior to screening.
  • Use of ophthalmic products, including eye drops and/or ophthalmic ointments, within 3 weeks prior to screening.
  • Any other ocular condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Investigational Product Mostrar mais linhas

    Female participants aged 18 to 60 years with clinically confirmed sensitive skin will receive the investigational product and undergo dermatological and ophthalmological safety assessments throughout the study.

    Other: Blancy Pro

Interventions

  • OtherBlancy Pro

    Blancy Pro is a cosmetic product evaluated for safety and tolerability in female participants with clinically confirmed sensitive skin through dermatological and ophthalmological assessments.

06

What researchers measure

Primary outcomes

  1. Dermatological and Ophthalmological Safety Assessment

    Evaluation of the safety of the investigational product under real-world conditions of use by assessing the absence of dermatological and ophthalmological irritation and capturing participant-reported discomfort sensations in individuals with sensitive skin.

    Time frame: Baseline (D0); D21

07

Study locations

1 site
  • Grupo Medcin
    Osasco, São Paulo 06023-070, Brazil
08

References and documents

Individual participant data

Plan to share: No — No plan has been established to share individual participant data (IPD) collected during this study. Participant confidentiality and privacy will be protected in accordance with applicable regulations and institutional policies.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Sep 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 19, 2026
StartActual
Jul 29, 2026
Primary completionActual
Sep 4, 2026
CompletionActual
Sep 4, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Start date
Jul 20, 2026→Jul 29, 2026
Nov 2, 2026
Primary completion
Sep 3, 2026→Sep 4, 2026 (actual)
Nov 2, 2026
Study completion
Sep 3, 2026→Sep 4, 2026 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Start date Jul 20, 2026→Jul 29, 2026
    Primary completion Sep 3, 2026→Sep 4, 2026 (now actual)
    Study completion Sep 3, 2026→Sep 4, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07771998
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Jul 29, 2026
Primary completion
Sep 4, 2026
Completion
Sep 4, 2026
Last update
Nov 2, 2026

Study contacts

Sergio Schalka
principal investigator · Grupo Medcin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion